ロード中...
Elevated CRB3 expression suppresses breast cancer stemness by inhibiting β‐catenin signalling to restore tamoxifen sensitivity
Tamoxifen is a first‐line drug for hormone therapy (HT) in oestrogen receptor‐positive breast cancer patients. However, 20% to 30% of those patients are resistant to tamoxifen treatment. Cancer stem cells (CSCs) have been implicated as one of the mechanisms responsible for tamoxifen resistance. Our...
保存先:
| 出版年: | J Cell Mol Med |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6010813/ https://ncbi.nlm.nih.gov/pubmed/29602199 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jcmm.13619 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|